Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Eye opening and PSD95 are required for long-term potentiation in developing superior colliculus.

Proceedings of the National Academy of Sciences of the United States of America | 2013

The only major glutamate receptor membrane-associated guanylate kinase scaffolds expressed in the young superficial superior colliculus (SC) are synapse-associated protein 102 (SAP102) and postsynaptic density protein 95 (PSD95). In this, as in all visual brain regions examined, synaptic PSD95 increases rapidly following simultaneous eyelid opening (EO). We show that EO and PSD95 are necessary for SC NMDA receptor (NMDAR)-dependent long-term potentiation (LTP) and this LTP is eliminated or reinstated by manipulating EO. PSD95 knockdown (KD) in vivo blocks this LTP, but not long-term depression, and reduces frequencies of miniature AMPA receptor and NMDAR currents with no change in presynaptic release. Furthermore, miniature NMDAR currents after PSD95 KD show an activity-triggered calcineurin sensitivity that is normally only found in the pre-EO period when SAP102 binds mixed GluN2A/GluN2B NMDARs. These data indicate that young SC LTP arises from PSD95 unsilencing of silent synapses, that unsilencing is labile in young brain, and that even though SAP102 and PSD95 can bind the same NMDARs, only PSD95 enables SC synaptic maturation.

Pubmed ID: 23267080 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

None found

Associated grants

  • Agency: NEI NIH HHS, United States
    Id: R01 EY014074
  • Agency: NEI NIH HHS, United States
    Id: EY014074

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Anti-Chapsyn-110/PSD-93 Antibody (antibody)

RRID:AB_2277296

This monoclonal targets Chapsyn-110/PSD-93

View all literature mentions

Anti-PSD-95 Antibody (antibody)

RRID:AB_2292909

This monoclonal targets PSD 95

View all literature mentions